T-helper/T-regulator lymphocyte ratio as a new immunobiological index to quantify the anticancer immune status in cancer patients

In Vivo

Volumn 22, Issue 5, 2008, Pages 647-650

  Brivio, F ^a   Fumagalli, L ^a   Parolini, D ^a   Messina, G ^a   Rovelli, F ^a   Rescaldani, R ^a   Vigore, L ^a   Vezzo, R ^a   Vaghi, M ^a   Di Bella, S ^a   Lissoni, Paolo ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Anticancer immunity; Immunosuppression; Lymphocytes; T regulator lymphocytes

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HELPER CELL; HUMAN; IMMUNE DEFICIENCY; LUNG NON SMALL CELL CANCER; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTASIS; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 53849147594     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Herberman RB: Design of clinical trials with biological response modifiers. Cancer Treat Rep 69: 1161-1166, 1985.
2. Foon KA: Biological response modifiers: the new immunotherapy. Cancer Res 49: 1621-1627, 1989.
3. Rosenberg SA: The immunotherapy and gene therapy of cancer. J Clin Oncol 10: 180-199, 1992.
4. Woijtowicz-Praga S: Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 20: 165-177, 1997.
5. von Boehmer H: Mechanism of suppression by suppressor T-cells. Nat Immunol 6: 338-344, 2005.
6. Riesco A: Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer 25: 135-140, 1970.
7. Claman HN: Corticosteroids and the immune system. Adv Exp Med Biol 245: 203-210, 1998.
8. Lissoni P, Brivio F, Fumagalli L, Di Fede G and Brera G: Enhancement of the efficacy of chemotherpy with oxaliplatin plus 5-fluorouracil by pre-treatment with IL-2 subcutaneous immunotherpy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy. In Vivo 19:1077-1080, 2005.
9. Cobleigh MA, Braun DP and Harris JE: Quantitation of lymphocytes and T cell subsets in patients with disseminated cancer. J Natl Cancer Inst 64: 1041-1045, 1980.
10. Dillman RO, Koziol JA, Zavanelli MI, Beauregard JC, Halliburton BL, Glassy MC and Royston I: Immuno-incompetence in cancer patients. Cancer 53: 1484-1491, 1984.
11. Lissoni P, Barni S, Tancini G, Viviani S, Rovelli F, Rescaldani R and Fiorelli G: Effects of cancer chemotherapy on the relation between serum levels of soluble interleukin-2 receptors and CD4/CD8 ratio in patients with solid neoplasms. J Biol Regul Homeost Agents 3: 131-133, 1989.
12. Levy JA: Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 57: 183-186, 1993.
13. Atzpodien J and Kirchner H: Cancer, cytokines and cytotoxic cells. Klin Wochenschr 68: 1-11, 1990.
14. Whittington R and Faulds D: Interleukin-2. Drugs 46: 446-483, 1993.
15. Kishimoto T: The biology of interleukin-6. Blood 74: 1-10, 1989.
16. Moore KW, O'Garra A, de Waal-Malefyt R, Vieira P and Mosmann TR: Interleukin-10. Ann Rev Immunol 11: 165-172, 1993.
17. Lissoni P, Barni S, Rovelli F and Tancini G: Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentrations. Oncology 48: 125-127, 1991.
18. + immunoregulatory T-cells is antigen non-specific. J Immunol 164: 183-190, 2000.
19. + suppressor T-cells: more questions than answers. Nat Rev Immunol 2: 389-400, 2002.
20. Zou W: Regulatory T-cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307, 2006.
21. Ziegler SF: FOXp3 of mice and men. Ann Rev Immunol 24: 209-226, 2006.
22. +CTLA-4 high T-regulatory cells with target alloantigen specificity. J Immunol 173: 2866-2876, 2004.
23. + high regulatory cells in human peripheral blood. J Immunol 167: 1245-1253, 2001.
24. + regulatory T-cells. Semin Immunol 16: 89-98, 2004.
25. + T-regulatory cells, immunotherapy of cancer and interleukin-2. J Immunother 28: 120-128, 2005.
26. + regulatory T-cells in patients with gastrointestinal malignancies: possible involvement of regulatory T-cells in disease progression. Cancer 98: 1089-1093, 2003.
27. + regulatory T-cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34: 336-344, 2004.
28. Kunutso KL,Disis ML and Salazar LG: CD4 regulatory T-cells in human cancer pathogenesis. Cancer Immunol Immunother 556: 2471-2485, 2007.
29. + regulatory T-cells in patients treated with high-dose interkleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24: 1169-77, 2006.